Semnur Pharmaceuticals, Inc.
SMNR
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$19M
▼ -3320.4% YoY
Op. Margin
–
ROIC
-548.57%
▼ -5483.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▼ -21.2% YoY
Op. Cash Flow (TTM)
-$11M
▼ -20.0% YoY
Net Debt
$2M
Cash & Equiv.
$54K
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with SMNR
Semnur Pharmaceuticals (SMNR) in three numbers
Questions about Semnur Pharmaceuticals
Is Semnur Pharmaceuticals a high-quality business?
Semnur Pharmaceuticals scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is revenue growth at 0.0%. The Quality tab shows every check against its target.
Does Semnur Pharmaceuticals (SMNR) pay a dividend?
No. Semnur Pharmaceuticals (SMNR) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 133.0% buyback yield. The Dividends tab shows its cash returns.
Source: 10-Q filed 4 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in SMNR's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SMNR
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.